The current data do not help us to understand whether the assessment of IL-34/BRD4 content in IBD biopsy samples could be useful in the management of these patients nor whether the activation of the BRD4/IL-34 axis can influence the responsiveness to specific drugs used in IBD. This evidence concerns the gene BRD4 and inflammatory bowel disease.